Skip to content

Study · Measured the body's own peptide · 2006

4 results

Salivary LL-37 secretion in individuals with Down syndrome is normal.

Bachrach G, Chaushu G, Zigmond M, Yefenof E, Stabholz A, Shapira J, Merrick J, Chaushu S

Journal of dental research1 Oct 2006Cited by 26 (Europe PMC)

PMID16998135 (opens in a new tab)DOI10.1177/154405910608501012 (opens in a new tab)PepBankPUB-16998135
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Natural levels measured4

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01HumanEndogenous levelObservational studyOther

    In saliva from young individuals with Down syndrome and healthy controls, the body's own LL‑37 and its precursor hCAP18 were detected in whole saliva but not in parotid saliva.

    In plain wordsThe body's own LL‑37 was found in whole saliva but not in saliva from the parotid gland.

    Peptide
    LL-37
    Outcome
    Not applicableSalivary LL-37 detection by saliva type
    Study

    n: not reported in source

    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    LL-37 and human cathelicidin antimicrobial protein (hCAP18) were detected in whole but not in parotid saliva. hCAP18 was more abundant than LL-37.
    1 context sentence
    Summary · context
    In the present study, levels of LL-37 and its hCAP18 precursor were measured in saliva samples from young individuals with Down syndrome and compared with levels in those from age-matched healthy controls.

    This result measures the body's own LL-37. Nobody was given the peptide. It is not evidence about taking it.

  2. 02HumanEndogenous levelObservational studyOther

    In whole saliva, the precursor hCAP18 was more abundant than the body's own LL‑37.

    In plain wordsIn saliva, the precursor hCAP18 was more plentiful than the body's own LL‑37.

    Peptide
    LL-37
    Outcome
    Not applicableSalivary LL-37 abundance relative to hCAP18
    Study

    n: not reported in source

    Comparator
    hCAP18
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    LL-37 and human cathelicidin antimicrobial protein (hCAP18) were detected in whole but not in parotid saliva. hCAP18 was more abundant than LL-37.
    1 context sentence
    Summary · context
    In the present study, levels of LL-37 and its hCAP18 precursor were measured in saliva samples from young individuals with Down syndrome and compared with levels in those from age-matched healthy controls.

    This result measures the body's own LL-37. Nobody was given the peptide. It is not evidence about taking it.

  3. 03HumanEndogenous levelObservational studyOther

    In young individuals with Down syndrome, salivary LL‑37 concentrations were higher than in age-matched healthy controls.

    In plain wordsYoung people with Down syndrome had higher levels of the body's own LL‑37 in saliva than healthy peers.

    Peptide
    LL-37
    Outcome
    IncreaseSalivary LL-37 concentration
    Study

    n: not reported in source

    Comparator
    Age-matched healthy controls
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    The concentrations of salivary hCAP18 and LL-37 were found to be higher in individuals with Down syndrome than in healthy controls, but their secretion rates were similar.
    1 context sentence
    Summary · context
    In the present study, levels of LL-37 and its hCAP18 precursor were measured in saliva samples from young individuals with Down syndrome and compared with levels in those from age-matched healthy controls.

    This result measures the body's own LL-37. Nobody was given the peptide. It is not evidence about taking it.

  4. 04HumanEndogenous levelObservational studyOther

    In young individuals with Down syndrome, the secretion rate of LL‑37 was similar to that in age-matched healthy controls.

    In plain wordsYoung people with Down syndrome released the body's own LL‑37 into saliva at a similar rate to healthy peers.

    Peptide
    LL-37
    Outcome
    No significant changeSalivary LL-37 secretion rate
    Study

    n: not reported in source

    Comparator
    Age-matched healthy controls
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    The concentrations of salivary hCAP18 and LL-37 were found to be higher in individuals with Down syndrome than in healthy controls, but their secretion rates were similar.
    1 context sentence
    Summary · context
    In the present study, levels of LL-37 and its hCAP18 precursor were measured in saliva samples from young individuals with Down syndrome and compared with levels in those from age-matched healthy controls.

    This result measures the body's own LL-37. Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    11 Oct 2026, 00:50 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.